We are live on ! Find out more
PRVL

Prevail Therapeutics Inc. Common Stock
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

Back to rankings

Fund managers haven’t disclosed any holdings of PRVL yet.

PRVL Hedge Fund Activity: Q1 2021 in Review

0 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q1 2021, worth a combined $0 — down 100% from $648M a quarter earlier.

Sellers outnumbered buyers: 92 funds closed out of PRVL and 0 opened new positions — a net loss of 92 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was OrbiMed, exiting entirely with an estimated $319M sold.

  • 0 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q1 2021, down from 93 in Q4 2020.
  • Funds reported $0 of Prevail Therapeutics Inc. Common Stock stock for Q1 2021, down 100% quarter-over-quarter.
  • 0 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q1 2021 and 92 closed out, a net change of -92 holders.
  • The largest Prevail Therapeutics Inc. Common Stock seller in Q1 2021 was OrbiMed, an estimated $319M sold.

Based on aggregated 13F filings for Q1 2021.